To say this past year has been like no other is an understatement. But for the pharmaceutical industry, 2020 has been something of a defining moment.
After being in the crosshairs over pricing, drug companies were suddenly seen as lifeboats that could rescue the world from the Covid-19 pandemic.
The sudden turn of events has cast the industry in a different light, but arguably, may not have changed its fortunes in the long run. The pandemic has thrown into sharp relief the debate over profits, innovation, and intellectual property rights on one side, and affordability and access on the other. And 2021 may prove to be a moment of reckoning for all concerned.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect